Novartis International AG said that Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration or TGA have granted approval for Gilenya 0.5 mg as a first-line, oral disease-modifying therapy for the treatment of relapsing-remitting multiple sclerosis.
The company stated that the data from a two-year placebo- controlled study showed a reduction in relapse rate of 54% compared with placebo.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309